Last updated: 2026-09-07 14:31:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Halozyme Therapeutics, Inc. (HALO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $110.18, with a market capitalization of $12.51B and a P/E ratio of 30.24. Over the past 52 weeks, its price has ranged from $61.23 to $111.22. This page covers its latest market performance, valuation, price trends and company information.
$12.51B | |
$109.91 | |
$111.22 | |
$2.60 | |
$110.76 | |
780.38K | |
1.97M | |
30.24 | |
$111.22 | |
$61.23 | |
-- | |
-- |
Halozyme Therapeutics, Inc. (HALO) last closed at $110.76 as of 2026-09-04 23:58:00, unchanged from the previous close of $110.76.
During the latest regular trading session, HALO traded between $2.60 and $111.22, with a volume of 780.38K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Halozyme Therapeutics, Inc. (HALO) moved from $106.92 to $110.18, representing a gain of 3.05% ($3.26).
The stock traded between $103.47 and $111.22 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1.42 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 97.9%
HALO is currently trading at $110.18, placing it 97.9% of the way from its 52-week low of $61.23 to its 52-week high of $111.22. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 423 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Halozyme Therapeutics, Inc. (HALO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.